An antibody-free blood probe targets rheumatic heart disease

Early rheumatic heart disease can be slowed with inexpensive penicillin, yet many low-resource settings lack ultrasound, refrigerated reagents and specialists. A Ben-Gurion University team designed a synthetic polymer probe whose targeting peptides recognize endothelial-cell adhesion molecules in blood and produce a fluorescent readout of inflammation. It avoids fragile animal-derived antibodies and complex cold-chain logistics, while the modular backbone can swap peptides for other vascular or inflammatory diseases. Current sensitivity remains in the microgram range, whereas early markers often require nanogram detection. This is a platform demonstration, not an approved diagnostic, and it has not yet shown improved patient outcomes.